ReviewLeukemia2002
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.
Review in Leukemia, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.Leukemia & lymphoma · 2017Trial
- High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study.Annals of hematology · 2007Trial
- Trial
- Advances in Targeting BCR-ABLMolecules (Basel, Switzerland) · 2026Review
- Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia.Cell death & disease · 2024Article
- Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells.Iranian journal of basic medical sciences · 2023Article
- The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.Scientific reports · 2016Article
- Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model.International journal of molecular sciences · 2015Article
- Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.Journal of cancer research and clinical oncology · 2012Article
- The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.The AAPS journal · 2011Review
- Heat shock protein 90: the cancer chaperone.Journal of biosciences · 2007Review
- Chaperone-rich cell lysates, immune activation and tumor vaccination.Cancer immunology, immunotherapy : CII · 2006Review
- Article
- Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.Leukemia · 2004Review
- Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy.British journal of cancer · 2004Article
- Article
- Imatinib sensitizes CLL lymphocytes to chlorambucil.Leukemia · 2004Article
- Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.Journal of cancer research and clinical oncology · 2004Review
- Alterations in the apoptotic machinery and their potential role in anticancer drug resistance.Oncogene · 2003Review
- Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.Wiener klinische Wochenschrift · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical phase I/II studies with the Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec, formerly STI571) for the treatment for chronic myelogenous leukemia (CML) demonstrated the safety and the remarkable efficacy of this molecularly targeted agent. However, a significant proportion of patients treated in the chronic phase of the disease after having failed interferon alpha (IFN) remain predominantly Philadelphia chromosome positive (Ph(+)), suggesting a risk of later relapses. Furthermore, results in blast crisis patients revealed a high frequency of relapses or resistance to imatinib. To circumvent resistance, improve response rates, or prolong survival, pre-clinical evaluations of combinations of imatinib with other agents have been pursued. Some of these have already been translated into clinical studies. Here, we first summarize evidence from pre-clinical studies on new combination regimens with imatinib in the treatment of CML. Second, we analyze preliminary clinical data of ongoing combination studies. Finally, we provide a summary of approaches that use novel antileukemic agents with molecularly characterized modes of action.
Indexed as
Identifiers
12094245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.